Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604 Trial in 1L Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

 Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604 Trial in 1L Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer

Shots:

  • The P-III KEYNOTE-604 study involves assessing of Keytruda (pembrolizumab, 200 mg) + etoposide + Pt CT vs PBO + etoposide +PT CT in 453 patients newly diagnosed with ES-SCLC
  • The P-III study resulted in improvement in PFS and OS but the OS results did not meet statistical significance per the pre-specified statistical plan, safety profile was consistent
  • Merck & Co’s (MSD outside the United States and Canada) Keytruda is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 & PD-L2, activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article | Ref: Merck & Co | Image: Signbox

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post